Stocktoria
ZEVRA THERAPEUTICS, INC. ZVRA
ZEVRA THERAPEUTICS, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $106.5M | $23.6M | $27.5M | $10.2M | $28.6M | $13.3M | $12.8M | $0 | — | — |
| R&D expense | — | — | — | — | $10.2M | $8.8M | $19.4M | $41.8M | $20.6M | $20.5M |
| SG&A expense | $77.6M | $54.9M | $34.3M | $15.0M | — | — | — | — | — | — |
| Operating income | -$62.9M | -$87.0M | -$49.6M | -$42.6M | $7.7M | -$5.6M | -$20.3M | -$55.9M | -$33.4M | -$37.5M |
| Interest expense | — | — | $1.5M | $335,000 | $226,000 | $4.8M | $4.9M | $5.5M | $5.8M | $5.5M |
| Income tax | $3.4M | $15.4M | $0 | -$33,000 | $34,000 | -$34,000 | -$22,000 | -$126,000 | -$43,000 | -$15,000 |
| Net income | $83.2M | -$105.5M | -$46.0M | -$26.8M | -$8.6M | -$12.8M | -$24.5M | -$56.5M | -$43.4M | -$16.5M |
| EPS (diluted) | $1.35 | $-2.28 | — | — | $-2.11 | $-3.21 | — | — | — | — |
| Operating cash flow | -$1.6M | -$69.7M | -$33.5M | -$18.7M | $10.4M | -$1.9M | -$23.7M | -$54.2M | -$33.1M | -$29.8M |
| Free cash flow | -$2.4M | -$69.7M | -$33.8M | -$18.8M | $10.3M | -$2.0M | -$23.8M | -$54.2M | -$33.3M | -$30.4M |
| Cash & equivalents | $62.4M | $33.8M | $43.0M | $65.5M | $112.3M | $4.2M | $3.2M | $18.4M | $10.9M | $16.8M |
| Inventory | $1.7M | $2.0M | $0 | $671,000 | — | — | — | — | — | — |
| Total assets | $284.7M | $178.1M | $172.3M | $115.3M | $132.9M | $11.2M | $10.5M | $26.7M | $52.5M | $84.9M |
| Total liabilities | $130.1M | $138.5M | $110.5M | $40.2M | $5.8M | $77.6M | $85.0M | $93.3M | $110.0M | $103.6M |
| Shareholders' equity | $154.7M | $39.7M | $61.9M | $75.1M | $101.7M | -$66.4M | -$74.5M | -$66.6M | -$57.5M | -$18.7M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +350.9% | -14.0% | +170.3% | -64.5% | +115.6% | +3.5% | — | — | — | — |
| Free cash flow growth | — | — | — | -282.0% | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.